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Abstract
: The management of patients with unruptured aneurysms remains controversial. Patients with unruptured
aneurysms may suffer intracranial haemorrhage, but the incidence of this event is still debated;
endovascular treatment may prevent rupture, but involves immediate risks. Hence, the balance of risks
and benefits of endovascular treatment is uncertain. Here, we report the design of the TEAM trial, the first
international, randomized, controlled trial comparing conservative management with endovascular
treatment. Primary endpoint is mortality and morbidity (modified Rankin Score ≥ 3) from intracranial
haemorrhage or treatment. Secondary endpoints include incidence of hemorrhagic events, morbidity
related to endovascular coiling, morphological results, overall clinical outcome and quality of life. Statistical
tests compare between probabilities at 5- and 10-years of 1/mortality from haemorrhage related to the
lesion, excluding per-operative complications; 2/mortality from haemorrhage or from complications of
treatment; 3/combined disease or treatment related mortality and morbidity in the absence of other
causes of death or disability. The study will be conducted in 60 international centres and will enrol 2,002
patients equally divided between the two groups, a size sufficient to achieve 80% power at a 0.0167
significance to detect differences in 1) disease or treatment-related poor outcomes from 7–9% to 3–5%;
2) overall mortality from 16 to 11%. Duration of the study is 14 years, the first three years being for patient
recruitment plus a minimum of 10 years of follow-up. The TEAM trial thus offers a means to reconcile the
introduction of a new approach with the necessity to acknowledge uncertainties.
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Background
The care of patients with unruptured aneurysms has been
described as the most vexing scientific question confront-
ing neurosurgeons, neurologists and interventional neu-
roradiologists [1,2]. The best management of patients
with asymptomatic intracranial aneurysms is currently
uncertain. The prevalence of intracranial aneurysms has
been estimated at 1 to 2% of the adult population but
with the increasing availability of non-invasive imaging of
the brain in an aging population, unruptured aneurysms
are increasingly being discovered [3-5].
Most aneurysms remain asymptomatic until the day they
rupture, an event that occurs with an annual incidence of
8–10/100,000 in the overall population [3-5]. Subarach-
noid haemorrhage (SAH) is associated with a high mor-
bidity and mortality (45–75%) despite the advances of
modern surgical and medical management [6,7]. Thus a
preventive treatment strategy is appealing. The annual risk
of bleeding from an unruptured aneurysm is debated, but
most series and meta-analysis have reported a small
annual risk, between 0.5–2% [4-7] with major morbidity
or death affecting up to 60% of those patients with even-
tual ruptures [7]. Any preventive treatment should there-
fore be very safe. Endovascular treatment can prevent
rupture but involves immediate risks to the patient [8-13].
Furthermore, successful treatment does not eliminate all
risks [14,15].
The efficacy of endovascular treatment in the prevention
of SAH remains unknown [16,17]. An international rand-
omized trial has shown that endovascular treatment is
safe and effective, and does improve the outcome of
patients treated after subarachnoid haemorrhage as com-
pared to surgical clipping, but this finding cannot be
extrapolated to unruptured lesions [18].
Hence, the balance of the risks and benefits of coiling is
uncertain. Nevertheless coiling of unruptured aneurysms
is becoming the most frequent procedure performed in
endovascular centres [19].
Prevention is justified when risks of treatment are low and
when benefits have been supported by valid trials.
Patients with unruptured aneurysms have never been the
subjects of a randomized trial. While medicine only has
an obligation of means, prevention has an obligation of
results, because prevention only offers potential benefits
and exposes healthy individuals to a certain risk [20]. The
clinical dilemma: "Are patients with unruptured aneu-
rysms best managed conservatively until definite indica-
tions arise or with endovascular treatment" can only find
a resolution by resorting to the rigorous methodology of
the randomized clinical trial [21-27].
We report the design of the TEAM trial (Trial on Endovas-
cular Aneurysm Management), the first and currently only
randomized trial on the management of unruptured
aneurysms eligible to endovascular treatment.
Overview of study design
TEAM is an international, randomized, multicenter, con-
trolled trial comparing the combined mortality and mor-
bidity (modified Rankin Scale (mRS) ≥ 3) from
intracranial haemorrhage or treatment in patients with
unruptured aneurysms treated by conservative manage-
ment (or deferral of treatment for 10 years or until definite
indications are thought to have arisen) as compared to
endovascular coiling.
The study is designed as a pragmatic trial. All candidates
for endovascular treatment of one or more unruptured
intracranial aneurysms are potential participants. Unrup-
tured aneurysms may be recently discovered or prevalent.
If they accept, subjects will be randomized to one of the
two arms of the trial: Conservative management or
endovascular management.
Both groups will be advised to obtain medical treatment
for hypertension if necessary and will receive counselling
for behavioural risk factor modelling (smoking or exces-
sive drinking) when indicated. A non-invasive (MRA or
CTA) or catheter angiogram and a baseline CT-scan or
MRI of the brain are required to enter the study. These
studies should demonstrate the unequivocal presence of a
saccular aneurysm ≥ 3 mm treatable by endovascular
methods. A catheter angiogram is required if there is
doubt. Imaging studies will be reviewed centrally. Both
treatments will be standardized. Patients will be followed
similarly for a minimum of 10 years.
The study will be conducted in 60 international centers.
The entire study will enrol 2002 patients equally divided
between the 2 groups, a size sufficient to achieve 80%
power at a 0.0167 significance to detect differences in 1/
disease or treatment-related poor outcomes from 7–9% to
3–5% as judged by an independent committee masked to
treatment allocation; 2/overall mortality from 16% to
11%. The duration forecast for the study is 14 years, the
first 3 years being for patient recruitment plus a minimum
of 10 years of follow-up.
Secondary end points will include the incidence of hem-
orrhagic events in both groups, the morbidity related to
endovascular coiling, morphological results as assessed by
non-invasive imaging at 5 and 10 years, overall clinical
outcome (morbidity and mortality) at 5 and 10 years,
quality of life assessment (SF-36), and the level of distress
caused by the knowledge of the hemorrhagic risk using
the HADS questionnaire.Trials 2008, 9:43 http://www.trialsjournal.com/content/9/1/43
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Primary objective
The primary objective of the trial is to answer the ques-
tion: Do patients with eligible unruptured aneurysms
have a better clinical outcome at 10 years with endovascu-
lar or conservative management of their lesions (deferral
of treatment until definite indications are thought to have
arisen)?
Clinical outcome is defined as combined morbidity
(modified Rankin scale 3 or more) and mortality from
intracranial haemorrhage or from treatment (as judged by
an independent committee unaware of treatment alloca-
tion).
Secondary objectives
The secondary objectives include assessments of the 5 and
10-year risks of haemorrhage of patients of both groups,
of the overall morbidity and mortality, of the safety and
efficacy of endovascular treatment, of the morphological
evolution of lesions at 5 and 10 years (stability of occlu-
sion results of treatment and rate of growth of untreated
lesions as judged centrally), a comparison between qual-
ity of life measures between the 2 groups, as well as an
assessment of the psychological impact of harbouring
treated or untreated unruptured aneurysms.
Planned trial interventions
a. Conservative management
For patients randomized to the "conservative" arm, inva-
sive treatment is deferred for at least 10 years or until def-
inite indications are thought to have arisen (progressive
symptoms from mass-effect, haemorrhage or symptoms/
signs suggesting "impending" rupture such as IIIrd nerve
palsy). Such events will be managed appropriately and
reported as "adverse events" within 48 hrs to the appropri-
ate committees. Certain centres may follow aneurysms by
periodic imaging, and could act upon demonstration of
"growth". The trial does not require such actions. These
"growths", which we expect to be rare, will be reported.
The final outcome, including treatment, considered
within a "conservative strategy" will be included in the
primary analysis.
b. Endovascular treatment
Endovascular treatment with coils will be performed
within 1 month of randomization, according to current
standards of practice, and under general anaesthesia, sys-
temic anticoagulation and antiplatelet therapy. Lesions
may recur at follow-up and physicians may elect to retreat
early recurrences. Re-treatments will be registered, and
recorded on Case Report Forms (CRFs) along with poten-
tial complications, but are considered intrinsic to
"endovascular management", within the same entry.
Many patients, including those with a family history,
present multiple unruptured aneurysms (20–40%),
sometimes associated with a previously treated, ruptured
aneurysm (25%). It is common, and in fact an integral
part of "endovascular management" to treat dominant
lesions or those felt to be at higher risk and observe
smaller ones or those felt to entail minor risks. We do not
wish to exclude such patients since they are a most fre-
quent indication for a preventive intervention. Rupture of
an untreated lesion may be difficult to differentiate from
bleeding of a treated one in the same patient, but this dis-
tinction is not pertinent since our main objective is to
assess the benefits of endovascular management for the
patient and not the efficacy of coiling of one aneurysm.
Treatment allocation
Patients will be allocated to one of two groups: a) conserv-
ative management or deferral of treatment for 10 years or
until indications have arisen or b) endovascular treat-
ment, using a centralized, minimisation procedure taking
into account patient and aneurysm characteristics to
ensure a balanced distribution between groups; minimi-
sation criteria have been set to the following (decreasing
hierarchical order): 1/type of presentation at diagnosis:
patients with a previously treated ruptured aneurysm or
not ; 2/aneurysm location: anterior versus posterior circu-
lation; 3/aneurysm dimensions: aneurysm greater than or
equal to 7 mm or not.
After on-line verification of the inclusion criteria the treat-
ment will be allocated to the patient; randomization is
through a web-based electronic Data Management system
that is available 24 hours a day, seven days a week.
Selection of subjects
The goal of the trial is to include any patient with unrup-
tured aneurysms considered a candidate for endovascular
management. To take into account ease of recruitment,
feasibility, generalizability, and ethical considerations, we
have kept entry criteria to a minimum (see Table 1). Sci-
entific and ethical considerations forbid a rigid a priori set
of criteria for equipoise. To enrol a patient in such a trial
necessitates the acknowledgment that we do not know for
certain what is the best management of his or her condi-
tion. In patients in whom risks of treatment may appear
reasonable, the risks of future haemorrhage may also be
modest. Another lesion presenting with characteristics
raising concerns in relation to haemorrhage may also
carry increased immediate procedural risks. Although we
favour a team approach regarding therapeutic decisions,
the final judgment on equipoise will rest upon the TEAM-
physician consulted by the patient. Reasons for not using
ISUIA subgroups results for selection criteria are explained
in [26]. Because some limits were thought to be indicated,
very small (<3 mm) and giant aneurysms (> 25 mm) were
excluded because of increased risks of perforation and
poor efficacy of coiling respectively. Patients with multi-Trials 2008, 9:43 http://www.trialsjournal.com/content/9/1/43
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ple aneurysms, including those that were successfully
treated after a rupture, perhaps associated with an
increased incidence of ruptures of associated unruptured
lesions, are patients for whom the research question is
crucial. Thus they can be recruited provided the ruptured
aneurysm is fully excluded from the circulation, to pre-
vent confounding the management of ruptured and
unruptured aneurysms. Other exclusion criteria concern
the need to exclude other causes of haemorrhage, patients
that cannot be assessed for the primary endpoint at the
end of the observation period, and patients that cannot be
managed endovascularly.
Frequency and duration of follow-up
Endpoint events are expected to occur with an incidence
of 0.5–2% per year in the "control group", with a morbid-
ity/mortality of 60% when they occur. Treatment aims at
long-term protection. This requires a relatively long fol-
low-up, proposed as a minimum observation period of 10
years. However, recruitment needs to be done within 3
years for this trial to be completed within a reasonable
time frame. Subjects from both trial arms will be followed
at one, six, twelve months, and yearly for 10 years. Tele-
phone contact will be performed at 6 month intervals to
minimize losses to follow-up. Clinical assessments will
comprise: 1) examination by an independent physician at
discharge (including an mRS), and by the treating physi-
cian at 1 and 6 months and yearly thereafter for 10 years;
2) evaluation by an independent and blinded interviewer
according to the mRS, the MoCA, SF-36, EQ-5D (Euroqol)
and HADS questionnaires at the time of recruitment, and
at one, 5 and 10 years.
Primary endpoint
The primary outcome, disease or treatment-related mor-
bidity or mortality, will be defined as the number of
patients with a mRS ≥3, from hemorrhagic events,
ischemic stroke from SAH or treatment, or operative com-
plications, for intent-to-treat populations at 1, 5 and 10
years.
The specific hypothesis is: The 10-year combined mortal-
ity and morbidity (M/M) related to unruptured aneu-
rysms observed in the conservative group will be
decreased from 8% to 4% (M/M of treatment and hemor-
rhagic events despite treatment as expressed by a mRS ≥ 3)
with endovascular treatment. Like any trial involving a
long follow-up period there will be a number of unrelated
events leading to death or morbidity; to keep sample size
reasonable, endpoints have to be adjudicated as disease or
treatment-related, or disease or treatment-unrelated [28].
Outcome measurements
a. Modus operandi
At the onset of the trial, a Clinical Events Committee
(CEC) has defined the types of events to be adjudicated as
disease or treatment-related, established criteria for those
events and set the algorithm to be followed in order to
classify a clinical event. The CEC proposal will be vetted
by the Data Safety and Monitoring Committee (DSMC).
Table 1: Selection criteria
Inclusion criteria
a. At least one documented subarachnoid aneurysm, never ruptured
b. Patient aged 18 or older
c. Life expectancy more than 10 years
Exclusion criteria
a. Patients with recent (less than 3 months) intracranial haemorrhage
b. Lesion characteristics unsuitable for endovascular treatment
c. Patients with a single extradural aneurysm
d. Aneurysms <3 mm or giant aneurysms (≥25 mm)
e. Patients with a poor outcome (Rankin scale ≥3) after the rupture, surgical or endovascular treatment of another aneurysm
f. Patients with incompletely treated aneurysms that have previously ruptured
g. Patients with associated arteriovenous malformations
h. Patients with new severe progressive symptoms in relationship with the aneurysm 
(sudden onset, severe persisting headaches suggestive of impending rupture, third-nerve palsy, mass-effect)
i. Patients with previous intracranial haemorrhage from unknown aetiology
j. Patients with multiple unruptured aneurysms in whom surgical clipping of one or many aneurysms is planned in addition to endovascular 
management
k. Patients with absolute contraindications to anaesthesia, endovascular treatment, or administration of contrast material, including low-
osmolarity agents or gadolinium
l. Pregnant patients
m. Patients unable to give informed consentTrials 2008, 9:43 http://www.trialsjournal.com/content/9/1/43
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The Endpoint Review Committee (ERC), following the
algorithm set by the CEC and approved by the DSMC and
operating blindly with respect to treatment allocation,
will adjudicate events based on censored clinical data doc-
umenting the event. Censoring will include digital manip-
ulation of radiology imaging data in order to prevent
adjudicators from being able to guess group allocation; it
will be performed by a dedicated Image Masking Center,
in Edinburgh.
b. Definitions
Criteria for the following events were set : intracranial
haemorrhage, aneurysm-related stroke, complications of
adjunct treatment to endovascular procedure and compli-
cations from mass effect due to the aneurysm. Other types
of events will be considered unrelated to the aneurysmal
disease or its treatment. Below, some categories are more
explicitly defined.
Treatment-related mortality or morbidity is defined as any
event leading to mortality or disability (mRS ≥3) occur-
ring within 2 months of randomisation or within 1
month of the endovascular procedure (delayed mortality
from operative morbidity is considered "operative" even
beyond 1 month) or due to complications of adjunct
treatment to endovascular procedure.
Disease-related morbidity or mortality is defined as any
event leading to mortality or disability (mRS ≥3) occur-
ring within 2 months of randomisation, or secondary to
hemorrhagic events, ischemic strokes related to the aneu-
rysm, or mass effect, for the remainder of the follow-up
period.
Hemorrhagic event is defined as 1) cross-sectional imag-
ing (CT or MRI) evidence of intracranial bleeding or 2)
acute headache and a lumbar puncture positive for haem-
orrhage or 3) acute third-nerve palsy if the aneurysm is in
the vicinity or 4) sudden death preceded by severe head-
aches or 5) intracranial bleeding proven by post-mortem
CT-scanning or autopsy or 6) unexplained sudden death.
Lethal hemorrhagic event is any mortality subsequent to
intracranial haemorrhage or its treatment.
"Impending rupture" in the conservative management
group. Patients with symptoms of impending rupture dur-
ing follow-up (see above in exclusion criteria), a relatively
rare event that could justify urgent endovascular or surgi-
cal treatment will be considered "failures" of conservative
management; "impending rupture" will thus be grouped
with "hemorrhagic events" in Kaplan-Meier analyses of
"survival without haemorrhagic event". However, such
cases will not be included in the primary outcome of the
conservative management group unless they exhibit mor-
tality or morbidity (mRS ≥ 3) from justified treatment.
This is warranted in a trial comparing elective invasive
treatment with "conservative management", since per-
forming interventions for clinical indications as they
occur is considered an integral part of "conservative man-
agement".
c. Primary outcome
The primary outcome, disease or treatment-related mor-
bidity or mortality, will be defined as the number of
patients with an mRS ≥3 from events classified as related
to the aneurysm or its treatment, for intent-to-treat popu-
lations at 1, 5 and 10 years. To minimize bias the inter-
viewers administrating the mRS and the committee
adjudicating the relation to the disease or treatment (the
ERC) will not be aware of group assignation.
d. Secondary outcomes
We will compare Kaplan-Meier (KM) curves of "survival
without hemorrhagic event" and "survival without hem-
orrhagic death" between the two groups for intent-to-treat
populations. In addition, we will repeat the same analyses
after removing cases of "impending rupture" from hemor-
rhagic events and deaths.
To measure morbidity/mortality of endovascular treat-
ment, all treated patients will be assessed by an independ-
ent neurologist before discharge and all severe adverse
events (SAE) will be reviewed by the Adverse Event Com-
mittee (AEC) to assure quality control on a case-by-case
basis. SAE, those that are life threatening or leading to pro-
longed hospitalizations, will be reported within 48 hours
to the data coordination centre that will transmit the
information to the DSMC. Severe procedure-related com-
plications will be reviewed in detail on a case by case basis
to assess if they were unavoidable, caused by a technical
error, or a breech in standard care. The DSMC will then
recommend an on-site visit or suspend recruitment in
individual centres if appropriate.
The death rate will be recorded for the intent-to-treat anal-
yses. It will be obtained by dividing the number of deaths
by the number of patients in each group. The number and
the severity of morbid events will be recorded for each
patient. The mRS will be assessed blindly at 1, 5 and 10
years.
Morphological results after treatment, at 6 months, and at
5 and 10 years will be categorized using a validated classi-
fication into 3 classes [14]. The number of patients show-
ing a recurrence, defined as aneurysmal growth or
recanalization, at follow-up imaging for all patients fol-
lowed at 5 and 10 years will determine the recurrence rate.
Interim angiographic results (invasive or non-invasive) at
6 months and 5 years, if there is no re-treatment, will helpTrials 2008, 9:43 http://www.trialsjournal.com/content/9/1/43
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determine a relationship between recurrences and hemor-
rhagic episodes in the treated group, if there is any.
The incidence of aneurysmal "growth" as documented by
non-invasive imaging in the group "treated conserva-
tively" may provide additional data, but is of unknown
significance. Images from all patients, at baseline, at the
end of treatment (for endovascular group), at 6 months,
and at 5 and 10 years will be analyzed centrally. An Imag-
ing Committee will determine aneurysm size for all
patients and criteria for "recurrences" and "aneurysmal
growth" on follow-up imaging studies. Aneurysms will be
compared over time to see if growth can be observed
which will be referred to as aneurysm "instability", or
remain the same and considered "stability". Aneurysm
growth in the control group and recurrences in the treated
group will be a surrogate endpoint that could predict
greater future risk of rupture.
A set of quality of life and anxiety/depression measures
will be collected with the 36-Item Short-Form Health Sur-
vey [29-33], the EQ-5D (Euroqol) and the HADS ques-
tionnaires at baseline, and at 1, 5 and 10 years. The SF-36
and EQ-5D is normally completed by the patients but the
present study will ensure the presence of interviewers to
ensure adequate completion and comprehension of the
questions; interviewer will ignore patient group assign-
ment. We will compare the absolute scores of both group,
the number of poor results (cut-off points of 7 for HADS
and 40 for SF-36) as well as the number of patients with
worsened scores with time between groups.
All patients will be assessed with the MoCA [34-37] at
baseline, and at 1, 5 and 10 years. This instrument was
preferred to the more widely used MMSE because it
includes some measures of executive functions (verbal flu-
ency and shortened version of Trail Making Test, part B)
as well as measures of naming abilities (animal naming)
which are lacking in the MMSE. In addition, for the assess-
ment of visuospatial abilities, the copy of the two embed-
ded geometric figures (from MMSE) was replaced by cube
copying and by clock drawing under command (with time
set at 10 after 11), which has been shown to be highly sen-
sitive to brain dysfunction [38]. Because cognitive func-
tions could be altered with treatment, but abnormalities
may not be discovered by standard examinations and
using trial tests, we will also perform detailed neuropsy-
chological assessments in 100 consecutive patients of
both groups at baseline and 6 months after randomiza-
tion in dedicated centres. Because of their high sensitivity,
tests of executive functions, attention and episodic mem-
ory will be administered. In agreement with the NINDS
recommendations, the following tests will be adminis-
tered in addition to the MoCA: the HVLT (12 words from
3 categories learned over three trials with delayed recall
and recognition), copy and delayed recall of the Rey com-
plex figure, BNT (confrontation naming of 60 pictures),
Digit Symbol subtest of the WAIS-III, COWAT (a letter flu-
ency test), Trail Making Test A and B. These measures are
similar to the ones examined following surgical clipping
[39].
Sample size calculation, planned analyses and control of 
error
As in any trials of hazardous surgery, early risks may be
followed by later benefit. Therefore the hazard ratio will
be unfavourable during the recruitment years while inter-
ventions are being performed [28,40]. Although more
sensitive tests will be performed to assess some hypothe-
ses (Kaplan-Meier methods for hemorrhagic events and
mortality), we used two-sided log rank tests to estimate
sample size. We took into account patients lost for analy-
ses, and adjusted the alpha for interim analyses. The total
size of the population would be approximately 2002 (tak-
ing into account 12% (or 240) patients being lost for anal-
ysis (8–10% of unrelated deaths [7] and 1–2% lost to
follow-up [28]), based on the following hypotheses: The
overall benefit of endovascular management could be
demonstrated with a total of 1688 patients, which is the
number to achieve 80% power at a 0.0167 significance
level (to account for 1–5-year interim analyses) to detect
a difference of 0.04 (hazard ratio: 0.4896) between the
null hypothesis that both proportions are 0.08 (the dis-
ease/treatment-related morbidity/mortality reaches 8% at
10 years) and the alternate hypothesis that the proportion
of the endovascular group is 0.04. These estimates are
compatible with 1) the recent metanalysis by Wermer [4]
for the risks of observation, with a 60% morbidity/mortal-
ity associated with a 1.2% yearly hemorrhagic rate and 2)
with the Atena registry on the morbidity and mortality of
endovascular treatment of unruptured aneurysms in
French centres [13]. Increasing the size of the population
to 2002 was elected to allow 1) to verify a significant dif-
ference under the same conditions between 7–9% in the
conservative group to 3–5% in the endovascular group
(Table 2) and 2) to achieve 80% power at a 0.0167 signif-
icance level to detect a difference of 0.05 (between 0.84
and 0.89) in the proportions surviving in groups 1 and 2
(difference in overall mortality; hazard ratio: 0.6684; pro-
portion lost to follow-up 0.02; Table 3). A significant dif-
ference in the overall mortality, an outcome resistant to
bias, could offer another convincing evidence for a bene-
fit.
Thus the control of alpha error will be implemented by
limiting interim analyses to two analyses once all patients
have completed one and 5 years of follow-up. The final
analysis will take into account multiplicity of testing for
the primary endpoint as well as for overall mortality. All
other secondary analyses will use a nominal P = 0.05. InTrials 2008, 9:43 http://www.trialsjournal.com/content/9/1/43
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order to describe how and when hemorrhagic events
occur, analyses will include Kaplan-Meyer life-table meth-
ods to assess the 5- and 10-year survival, and survival
without haemorrhage, among all those allocated immedi-
ate coiling (including the few who did not undergo it) and
all those allocated deferral of any intervention (including
the few who will eventually be operated on). The "sur-
vival" functions will be compared graphically and using a
log-rank statistic. The main statistical tests will involve
comparisons between the probabilities of mortality 1/
from haemorrhage, excluding per-operative complica-
tions, 2/from haemorrhage or from complications of
treatment, or 3/comparisons of the 5-year probabilities of
combined disease/treatment-related mortality/morbidity,
in the absence of other causes of death or disability.
Descriptive statistics will be done on demographic varia-
bles and potential risk factors to compare the two groups
at baseline. Means, standard deviations and range will be
presented for quantitative variables such as size of aneu-
rysms and frequency tables for categorical variables (such
as number of patients with a previous history of SAH, or
multiple aneurysms). Those statistics will be broken down
by centre and by treatment arm. Comparability of the
groups will be assessed through independent ANOVAs
Table 2: Sample sizes to detect a significant difference in disease or treatment-related combined morbidity/mortality. Numeric 
Results with Proportion Lost to Follow Up = 0.1200
Hazard Two-sided
Power N N1 N2 S1 S2 Ratio Alpha Beta
0.8007 1332 666 666 0.9000 0.9500 0.4868 0.0167 0.1993
0.8006 872 436 436 0.9000 0.9600 0.3875 0.0167 0.1994
0.8006 602 301 301 0.9000 0.9700 0.2891 0.0167 0.1994
0.8004 1947 974 973 0.9100 0.9500 0.5439 0.0167 0.1996
0.8002 1168 584 584 0.9100 0.9600 0.4328 0.0167 0.1998
0.8007 757 379 378 0.9100 0.9700 0.3230 0.0167 0.1993
0.8002 3223 1612 1611 0.9200 0.9500 0.6152 0.0167 0.1998
0.8002 1688 844 844 0.9200 0.9600 0.4896 0.0167 0.1998
0.8003 1001 501 500 0.9200 0.9700 0.3653 0.0167 0.1997
0.8000 6717 3359 3358 0.9300 0.9500 0.7068 0.0167 0.2000
0.8002 2758 1379 1379 0.9300 0.9600 0.5625 0.0167 0.1998
0.8004 1424 712 712 0.9300 0.9700 0.4197 0.0167 0.1996
Summary Statements: A two-sided log rank test with an overall sample size of 1688 subjects (of which 844 are in group 1 and 844 are in group 
2) achieves 80% power at a 0.0167 significance level to detect a difference of 0.0400 between 0.9200 and 0.9600 – the proportions surviving in 
groups 1 and 2, respectively. This corresponds to a hazard ratio of 0.4896. The proportion of patients lost during follow up was 0.1200.
Table 3: Sample sizes to detect a significant difference in overall mortality. Numeric Results with Proportion Lost to Follow Up = 
0.0200
Hazard Two-sided
Power N N1 N2 S1 S2 Ratio Alpha Beta
0.8002 1520 760 760 0.8200 0.8800 0.6442 0.0167 0.1998
0.8004 1089 545 544 0.8200 0.8900 0.5872 0.0167 0.1996
0.8003 2125 1063 1062 0.8300 0.8800 0.6861 0.0167 0.1997
0.8005 1437 719 718 0.8300 0.8900 0.6254 0.0167 0.1995
0.8001 3219 1610 1609 0.8400 0.8800 0.7332 0.0167 0.1999
0.8000 2002 1001 1001 0.8400 0.8900 0.6684 0.0167 0.2000
0.8001 5543 2772 2771 0.8500 0.8800 0.7866 0.0167 0.1999
0.8001 3025 1513 1512 0.8500 0.8900 0.7170 0.0167 0.1999
0.8000 12068 6034 6034 0.8600 0.8800 0.8476 0.0167 0.2000
0.8001 5194 2597 2597 0.8600 0.8900 0.7727 0.0167 0.1999
0.8000 46657 23329 23328 0.8700 0.8800 0.9179 0.0167 0.2000
0.8000 11271 5636 5635 0.8700 0.8900 0.8368 0.0167 0.2000
Summary Statements: A two-sided log rank test with an overall sample size of 2002 subjects (of which 1001 are in group 1 and 1001 are in 
group 2) achieves 80% power at a 0.0167 significance level to detect a difference of 0.0500 between 0.8400 and 0.8900 – the proportions surviving 
in groups 1 and 2, respectively. This corresponds to a hazard ratio of 0.6684. The proportion of patients lost during follow up was 0.0200.
Software: PASS 2000, Power Analysis and Sample Size for Windows; NCSS, Kaysville, UtahTrials 2008, 9:43 http://www.trialsjournal.com/content/9/1/43
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(quantitative data) or Mantel-Haentzel and χ2 tests (cate-
gorical data). Assuming comparability of groups across
centres, the primary outcome, disease or treatment-related
combined morbidity/mortality for intent-to-treat popula-
tions will be compared between groups through a z-test
for independent proportions at 1, 5 and 10 years. Similar
analyses will be done for disease or treatment-related
mortality. Secondary outcomes and overall morbidity will
be compared between groups through independent t-tests
(quantitative variables) or χ2 statistics (categorical data).
The analyses of neurological data at follow-up will control
for baseline data using logistic regression, ANCOVA or
Cox regression multivariate models. Finally, a logistic
regression will be used to find variables capable of predict-
ing haemorrhages or complications in both groups. The
method planned is a stepwise forward with alpha <0.05 to
enter a predictor. Possible predictors include the status of
the aneurysm (previous history of SAH vs. unruptured
only), size of the aneurysm (≥ 7 mm vs < 7 mm), location
(posterior vs. anterior circulation aneurysms), angio-
graphic results of endovascular treatment, as well as other
baseline characteristics.
Equipoise, randomization and ethical considerations
We cannot reliably compare the outcome following two
treatment options without resorting to randomization.
Genuine respect for subjects and human dignity requires
that the research meet scientific norms of excellence (here
randomization). The use of subjects can only be justified
when the objective is to provide unbiased results and thus
forward the knowledge regarding the disease or its treat-
ment. Thus we want to reach generalizable knowledge but
the physician's primary duty is to care for the individual
patient. And this is where the difficulty is, an apparent
opposition between generalizable knowledge and the care
of the particular patient. This does not mean that we are
bending the therapeutic obligation to current individuals
to meet the scientific requirements that will provide
knowledge to guide the treatment of future individuals.
The research question concerns first and foremost our cur-
rent patients, for whom no action has yet been proved
beneficial. Thus randomization is not only a scientific
solution to the problem of bias; it is also a practical way
of assuring the best possible outcome for each individual
patient. In the absence of evidence, by treating patients to
prevent ruptures we could cause more harm than by not
treating them. The best option for each individual is cur-
rently unknown. Until it can be asserted with confidence
that patients need to be treated, because they do better
with treatment than without, the "best" we can offer to
our patient is a chance to be treated and thus to be pro-
tected from rupture of the aneurysm, and an equal chance
not to be treated, and hence to be exempted from imme-
diate treatment complications. Hence, when the uncer-
tainty dominates, we offer randomization until the
uncertainty can be replaced by reliable evidence. Now,
how and when the reliability of evidence will be deter-
mined is a judgement to be delegated to an impartial and
independent group of persons, the DSMC [25,26].
We have the moral duty to determine how appropriate
our actions may be, actions that have so far only been
guided by fear of the disease and faith in our technologies.
We also have the duty to help the healthy individuals that
we have put into difficult decisional contexts by our own
technological progress, to understand that the uncertainty
cannot be simply resolved. We have the professional
responsibility not to act like if we knew.
Randomization is not giving up the decision to chance. It
is to opt for a rational, responsible choice, to suspend
judgment until there is evidence, to maximize chances of
a benefit for each individual patient while we remain
uncertain, and to act in a context that will promote knowl-
edge and progress, in the respect of patient autonomy.
Conclusion
Endovascular treatment is nowadays a standardized pro-
cedure that has routine applications in specialized centres.
An objective assessment of its value in unruptured aneu-
rysms is now necessary. A randomized trial can reconcile
the introduction of a new approach with the necessity to
acknowledge uncertainties, to scientifically assess poten-
tial benefits, and to assist healthy individuals alerted by
the discovery of an ominous condition, in a controlled
environment that respects and promotes their autonomy.
Availability and requirements
The study website: http://www.teamstudy.org
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HUNGARY
Budapest National Institute of Neurosurgery Szikora I.; Kulcsar Z.
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